课题基金 / 基金详情

Identification of novel co-factors for HIV Tat and Rev as therapeutic targets

Identification of novel co-factors for HIV Tat and Rev as therapeutic targets
鉴定 HIV Tat 和 Rev 的新辅助因子作为治疗靶点
批准号:
8505377
负责人:
Andrew P Rice
金额:
$18.39万
依托单位:
依托单位国家:
美国
项目类别:
财政年份:
2012
资助国家:
美国
项目状态:
已结题
起止时间:
2012-07-05 至 2014-06-30

项目摘要

项目成果

Andrew P Rice的其他基金

相似基金

相关文献

中文摘要
翻译
点击翻译按钮获取中文摘要
英文摘要
DESCRIPTION (provided by applicant): The goal of this project is to identify novel therapeutic targets for HIV-1 infection, focusing on cellular co- factors involved in the viral Tat protein or Rev protein function. Although it is not known how many cellular factors are involved in Tat and Rev function, recent studies and data mining have revealed that on the order of 50 cellular proteins are likely involved in these processes. The best understood cellular co-factor for Tat is a protein kinase complex termed P-TEFb. P-TEFb is composed of Cyclin T1 (CCNT1) as a regulatory subunit and CDK9 as the catalytic subunit; Tat binds directly to CCNT1. The best understood cellular co-factor for Rev is termed XPO1 (CRM1); Rev binds directly to XPO1. Nearly all processes in cells are carried out by multiprotein complexes which are thought to be the minimal functional unit. It is therefore likely that both CCNT1/CDK9 and XPO1 exist is several higher order multiprotein complexes and these complexes may be involved in Tat and Rev function. We have mined a recently published dataset that described the human nuclear complexome - the set of multiprotein complexes defined by a high-throughput co-immunoprecipitation/mass spec analysis. We have identified a number of novel cellular complexes that contain CCN1/CDK9 or XPO1. We will test the hypothesis that several of these complexes are involved in either Tat or Rev function. In our preliminary studies, we have obtained strong experimental support for this hypothesis. Importantly, our initial results also indicate that we will identify cellular factors that negatively regulate Tat activation of the HIV- LTR. Such negative acting factors have therapeutic potential in strategies to purge the latent HIV-1 reservoir in patients taking anti-viral drugs. Completion of the proposed work will reveal a number of potential therapeutic targets, especially some that may be useful for strategies to purge the reservoir of latent viruses in HIV-infected individuals.
期刊论文(1)
专著(0)
科研奖励(0)
会议论文
Developmental Core B
  • 批准号:
    10609476
  • 项目类别:
  • 资助金额:
    $28.9万
  • 财政年份:
    2021
  • 负责人:
    Andrew P Rice
  • 依托单位:
Developmental Core B
  • 批准号:
    10397170
  • 项目类别:
  • 资助金额:
    $178.53万
  • 财政年份:
    2021
  • 负责人:
    Andrew P Rice
  • 依托单位:
Imaging-base Automated Screen for Compounds that Induce P-TEFb
  • 批准号:
    9352533
  • 项目类别:
  • 资助金额:
    $23.78万
  • 财政年份:
    2017
  • 负责人:
    Andrew P Rice
  • 依托单位:
Role of NEAT1 lncRNA in HIV replication
  • 批准号:
    9292251
  • 项目类别:
  • 资助金额:
    $19.81万
  • 财政年份:
    2016
  • 负责人:
    Andrew P Rice
  • 依托单位:
国内基金
海外基金
帽结合蛋白(cap binding protein)调控乙烯信号转导的分子机制
  • 批准号:
    32170319
  • 项目类别:
    面上项目
  • 资助金额:
    58.00万元
  • 批准年份:
    2021
  • 负责人:
    董春海
  • 依托单位:
帽结合蛋白(cap binding protein)调控乙烯信号转导的分子机制
  • 批准号:
    --
  • 项目类别:
    --
  • 资助金额:
    58万元
  • 批准年份:
    2021
  • 负责人:
    董春海
  • 依托单位:
ID1 (Inhibitor of DNA binding 1) 在口蹄疫病毒感染中作用机制的研究
番茄EIN3-binding F-box蛋白2超表达诱导单性结实和果实成熟异常的机制研究
  • 批准号:
    31372080
  • 项目类别:
    面上项目
  • 资助金额:
    80.0万元
  • 批准年份:
    2013
  • 负责人:
    杨迎伍
  • 依托单位: